New drug cocktail aims to deepen remission in multiple myeloma patients

NCT ID NCT07671287

Not yet recruiting Disease control Sponsor: University of Heidelberg Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether adding the drug Teclistamab to a standard treatment regimen (Daratumumab, Lenalidomide, Bortezomib, Dexamethasone) improves outcomes for newly diagnosed multiple myeloma patients eligible for stem cell transplant. About 399 adults aged 18-70 will receive either the new combo or standard care, followed by maintenance therapy. The main goal is to see if more patients achieve undetectable cancer levels before starting maintenance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teclistamab, Daratumumab, Lenalidomide, Bortezomib, Dexamethasone
What this could lead to: If successful, this could lead to a more effective treatment combination for multiple myeloma, potentially achieving deeper remission before maintenance therapy.
What could go wrong: This is an early-stage Phase 3 trial not yet recruiting, so results are uncertain. The combination may cause significant side effects, and long-term benefits over standard care are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.